Smart jab can shrink head and neck cancer tumours within six weeks, trial finds - The Guardian
- Smart jab can shrink head and neck cancer tumours within six weeks, trial finds The Guardian
- ESMO 2025 – J&J brings a new Rybrevant use into the fold | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
- Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer The Manila Times
- ‘Smart jab’ shows promise in treating advanced head and neck cancer The Institute of Cancer Research
- Johnson & Johnson announces new results from Phase 1b/2 OrigAMI-4 study TipRanks